These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 23176363)
1. Prognostic value of tgfb1 protein in endometrioid adenocarcinoma. Soufla G; Sifakis S; Porichis F; Spandidos DA Eur J Clin Invest; 2013 Jan; 43(1):79-90. PubMed ID: 23176363 [TBL] [Abstract][Full Text] [Related]
2. FGF2 transcript levels are positively correlated with EGF and IGF-1 in the malignant endometrium. Soufla G; Sifakis S; Spandidos DA Cancer Lett; 2008 Feb; 259(2):146-55. PubMed ID: 18006148 [TBL] [Abstract][Full Text] [Related]
3. Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3 and cognate receptors in breast tumorigenesis. Soufla G; Porichis F; Sourvinos G; Vassilaros S; Spandidos DA Cancer Lett; 2006 Apr; 235(1):100-13. PubMed ID: 15949894 [TBL] [Abstract][Full Text] [Related]
4. microRNAs related to angiogenesis are dysregulated in endometrioid endometrial cancer. Ramón LA; Braza-Boïls A; Gilabert J; Chirivella M; España F; Estellés A; Gilabert-Estellés J Hum Reprod; 2012 Oct; 27(10):3036-45. PubMed ID: 22904162 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of Musashi-1 in endometrioid adenocarcinoma. Ma L; Xu YL; Ding WJ; Shao HF; Teng YC Int J Clin Exp Pathol; 2015; 8(5):4564-72. PubMed ID: 26191146 [TBL] [Abstract][Full Text] [Related]
6. Haptoglobin expression in endometrioid adenocarcinoma of the uterus. Nabli H; Tuller E; Sharpe-Timms KL Reprod Sci; 2010 Jan; 17(1):47-55. PubMed ID: 19801537 [TBL] [Abstract][Full Text] [Related]
7. Oestrogen regulated gene expression in normal and malignant endometrial tissue. O'Toole SA; Dunn E; Sheppard BL; Sheils O; O'Leary JJ; Wuttke W; Seidlova-Wuttke D Maturitas; 2005 Jun; 51(2):187-98. PubMed ID: 15917160 [TBL] [Abstract][Full Text] [Related]
8. Up-regulation of ERM/ETV5 correlates with the degree of myometrial infiltration in endometrioid endometrial carcinoma. Planagumà J; Abal M; Gil-Moreno A; Díaz-Fuertes M; Monge M; García A; Baró T; Xercavins J; Reventós J; Alameda F J Pathol; 2005 Dec; 207(4):422-9. PubMed ID: 16175655 [TBL] [Abstract][Full Text] [Related]
9. Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis. Romero-Pérez L; Castilla MÁ; López-García MÁ; Díaz-Martín J; Biscuola M; Ramiro-Fuentes S; Oliva E; Matias-Guiu X; Prat J; Cano A; Moreno-Bueno G; Palacios J Hum Pathol; 2013 Feb; 44(2):244-54. PubMed ID: 22974476 [TBL] [Abstract][Full Text] [Related]
10. Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas. Ozbudak IH; Karaveli S; Simsek T; Erdogan G; Pestereli E Gynecol Oncol; 2008 Mar; 108(3):603-8. PubMed ID: 18191183 [TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis. Yang Q; Ye ZY; Zhang JX; Tao HQ; Li SG; Zhao ZS Anat Rec (Hoboken); 2010 Dec; 293(12):2012-9. PubMed ID: 21089052 [TBL] [Abstract][Full Text] [Related]
12. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Soulitzis N; Karyotis I; Delakas D; Spandidos DA Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871 [TBL] [Abstract][Full Text] [Related]
13. Inhibin-βA subunit immunolabeling as a prognostic factor in endometrioid adenocarcinomas: a matter of evaluation? Mylonas I Arch Gynecol Obstet; 2011 Aug; 284(2):467-76. PubMed ID: 20865419 [TBL] [Abstract][Full Text] [Related]
14. The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma. Huang C; Huang R; Chang W; Jiang T; Huang K; Cao J; Sun X; Qiu Z Neoplasma; 2012; 59(1):52-61. PubMed ID: 22082308 [TBL] [Abstract][Full Text] [Related]
15. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Kamat AA; Merritt WM; Coffey D; Lin YG; Patel PR; Broaddus R; Nugent E; Han LY; Landen CN; Spannuth WA; Lu C; Coleman RL; Gershenson DM; Sood AK Clin Cancer Res; 2007 Dec; 13(24):7487-95. PubMed ID: 18094433 [TBL] [Abstract][Full Text] [Related]
16. Methylation profiles of endometrioid and serous endometrial cancers. Seeber LM; Zweemer RP; Marchionni L; Massuger LF; Smit VT; van Baal WM; Verheijen RH; van Diest PJ Endocr Relat Cancer; 2010 Sep; 17(3):663-73. PubMed ID: 20488783 [TBL] [Abstract][Full Text] [Related]
17. Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype. Watari H; Xiong Y; Hassan MK; Sakuragi N Gynecol Oncol; 2009 Jan; 112(1):229-34. PubMed ID: 19007976 [TBL] [Abstract][Full Text] [Related]
18. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Guidi AJ; Abu-Jawdeh G; Tognazzi K; Dvorak HF; Brown LF Cancer; 1996 Aug; 78(3):454-60. PubMed ID: 8697391 [TBL] [Abstract][Full Text] [Related]
19. Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis. Giatromanolaki A; Sivridis E; Gatter KC; Turley H; Harris AL; Koukourakis MI; Gynecol Oncol; 2006 Dec; 103(3):912-8. PubMed ID: 16837029 [TBL] [Abstract][Full Text] [Related]
20. Expression of maspin in endometrioid adenocarcinoma of endometrium. Li HW; Leung SW; Chan CS; Yu MM; Wong YF Oncol Rep; 2007 Feb; 17(2):393-8. PubMed ID: 17203179 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]